|
NZ591176A
(en)
*
|
2008-08-22 |
2012-11-30 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
|
US20120100100A1
(en)
|
2009-05-13 |
2012-04-26 |
Sharpless Norman E |
Cyclin dependent kinase inhibitors and methods of use
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
ES2689177T3
(es)
|
2010-04-13 |
2018-11-08 |
Novartis Ag |
Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
|
|
JP5959516B2
(ja)
|
2010-08-18 |
2016-08-02 |
ライフ テクノロジーズ コーポレーション |
電気化学的検出装置のためのマイクロウェルの化学コーティング法
|
|
MX379532B
(es)
|
2010-10-25 |
2025-03-10 |
G1 Therapeutics Inc |
Inhibidores de cdk.
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
US20120115878A1
(en)
*
|
2010-11-10 |
2012-05-10 |
John Vincent Calienni |
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
|
|
CA2818046A1
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
|
|
PE20140471A1
(es)
*
|
2011-01-04 |
2014-04-13 |
Novartis Ag |
Moduladores de la via del complemento y usos de los mismos
|
|
AU2014259534B2
(en)
*
|
2011-01-04 |
2016-05-19 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
|
|
PH12013502697A1
(en)
*
|
2011-07-01 |
2014-02-10 |
Novartis Ag |
Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
|
|
RU2014103250A
(ru)
*
|
2011-07-01 |
2015-08-10 |
Новартис Аг |
Комбинированная терапия
|
|
WO2013059634A1
(en)
|
2011-10-20 |
2013-04-25 |
The Regents Of The University Of California |
Use of cdk9 inhibitors to reduce cartilage degradation
|
|
US9194840B2
(en)
|
2012-01-19 |
2015-11-24 |
Life Technologies Corporation |
Sensor arrays and methods for making same
|
|
WO2013148748A1
(en)
*
|
2012-03-29 |
2013-10-03 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
CA2870019C
(en)
|
2012-04-26 |
2020-08-18 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
ES2710491T3
(es)
|
2012-06-28 |
2019-04-25 |
Novartis Ag |
Moduladores de la vía del complemento y sus usos
|
|
CN104640855B
(zh)
|
2012-06-28 |
2017-08-29 |
诺华股份有限公司 |
补体途经调节剂及其用途
|
|
ES2647124T3
(es)
|
2012-06-28 |
2017-12-19 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
|
|
WO2014002052A1
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
US9388199B2
(en)
|
2012-06-28 |
2016-07-12 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
AU2013288319A1
(en)
|
2012-07-12 |
2015-02-05 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
EP2742940B1
(en)
|
2012-12-13 |
2017-07-26 |
IP Gesellschaft für Management mbH |
Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
|
|
US9867825B2
(en)
*
|
2012-12-20 |
2018-01-16 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
EP3327144B1
(en)
|
2013-02-25 |
2020-03-25 |
Novartis AG |
Novel androgen receptor mutation
|
|
CN105189481A
(zh)
|
2013-03-13 |
2015-12-23 |
艾伯维公司 |
吡啶cdk9激酶抑制剂
|
|
MX2015012386A
(es)
|
2013-03-13 |
2016-02-03 |
Abbvie Inc |
Inhibidores de la cinasa cdk9.
|
|
CA2903538A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Pyrrolopyrimindine cdk9 kinase inhibitors
|
|
BR112015023356A2
(pt)
|
2013-03-14 |
2017-07-18 |
Abbvie Inc |
inibidores de quinase pirrol[2,3-b]piridina cdk9
|
|
UY35419A
(es)
|
2013-03-14 |
2014-10-31 |
Abbvie Inc |
Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
|
|
US20140271460A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly Active Anti-Neoplastic and Anti-Proliferative Agents
|
|
WO2014144596A2
(en)
*
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
CN105473140B
(zh)
|
2013-03-15 |
2018-04-10 |
G1治疗公司 |
在化学疗法期间对正常细胞的瞬时保护
|
|
CA2907704C
(en)
|
2013-03-21 |
2023-01-10 |
Giordano Caponigro |
Combination therapy for reversing b-raf inhibitor resistance comprising a second inhibitor based on genetic alterations
|
|
EP2986740B1
(en)
|
2013-04-16 |
2020-01-15 |
Memorial Sloan-Kettering Cancer Center |
Companion diagnostic for cdk4 inhibitors
|
|
CN105828822B
(zh)
*
|
2013-08-14 |
2019-10-18 |
诺华股份有限公司 |
用于治疗癌症的组合疗法
|
|
JP6479812B2
(ja)
*
|
2013-08-28 |
2019-03-06 |
ノバルティス アーゲー |
細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
TW201605857A
(zh)
*
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Ｃｄｋ８之醫療性抑制劑及其用途
|
|
US20160257688A1
(en)
*
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
AU2014354821A1
(en)
*
|
2013-11-27 |
2016-05-26 |
Novartis Ag |
Combination therapy comprising an inhibitor of JAK, CDK and PIM
|
|
US9476853B2
(en)
|
2013-12-10 |
2016-10-25 |
Life Technologies Corporation |
System and method for forming microwells
|
|
WO2015095840A1
(en)
*
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of cdk and erk inhibitors
|
|
CN105848656B
(zh)
|
2013-12-23 |
2019-10-25 |
诺华股份有限公司 |
药物组合
|
|
CN105848682A
(zh)
*
|
2013-12-23 |
2016-08-10 |
诺华股份有限公司 |
药物组合
|
|
KR101787680B1
(ko)
*
|
2013-12-31 |
2017-10-19 |
수안주 파마 코포레이션 리미티드 |
키나아제 억제제 및 이의 용도
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
KR20240110004A
(ko)
|
2014-03-14 |
2024-07-12 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
AU2015240465B2
(en)
|
2014-04-04 |
2020-02-27 |
Del Mar Pharmaceuticals |
Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
|
|
WO2015160986A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
KR101864589B1
(ko)
*
|
2014-05-28 |
2018-07-04 |
상하이 포천 파마슈티컬 씨오 엘티디 |
특정한 단백질 키나아제 억제제
|
|
CN105294737B
(zh)
*
|
2014-07-26 |
2019-02-12 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
JP2017535528A
(ja)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
組み合わせ治療
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP3206749B1
(en)
|
2014-10-14 |
2021-09-08 |
The Regents of the University of California |
The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
|
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
PT3218005T
(pt)
|
2014-11-12 |
2023-04-11 |
Seagen Inc |
Compostos que interagem com glicano e métodos de uso
|
|
US10138250B2
(en)
|
2014-12-12 |
2018-11-27 |
Crystal Pharmatech Co., Ltd. |
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
|
US9994579B2
(en)
|
2014-12-12 |
2018-06-12 |
Crystal Pharmatech Co., Ltd. |
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
|
CN105111215B
(zh)
*
|
2014-12-12 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
|
|
WO2016126889A1
(en)
*
|
2015-02-03 |
2016-08-11 |
G1 Therapeutics, Inc. |
Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
|
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
|
EP3273959A1
(en)
|
2015-03-25 |
2018-01-31 |
Novartis Ag |
Pharmaceutical combinations
|
|
SI3283058T1
(sl)
|
2015-04-16 |
2023-03-31 |
Novartis Ag |
Tableta ribocikliba
|
|
CN106146515B
(zh)
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
|
TWI696617B
(zh)
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
|
RU2695337C2
(ru)
|
2015-05-29 |
2019-07-23 |
Тейдзин Фарма Лимитед |
ПРОИЗВОДНОЕ ПИРИДО[3,4-d]ПИРИМИДИНА И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМАЯ СОЛЬ
|
|
CN105037236B
(zh)
*
|
2015-06-04 |
2017-07-28 |
苏州明锐医药科技有限公司 |
瑞博西尼中间体及其制备方法
|
|
CN106336412A
(zh)
*
|
2015-07-10 |
2017-01-18 |
南开大学 |
作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
|
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
|
CN105130992B
(zh)
*
|
2015-07-16 |
2018-02-09 |
苏州大学 |
具有激酶抑制活性的含氮杂环化合物、制备方法和用途
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3340986A1
(en)
|
2015-08-28 |
2018-07-04 |
Novartis AG |
A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
|
WO2017037576A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
|
|
WO2017037574A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
|
|
WO2017037587A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Combination of ribociclib and dabrafenib for treating or preventing cancer
|
|
EP3156406A1
(en)
|
2015-10-14 |
2017-04-19 |
ratiopharm GmbH |
Crystalline forms of ribociclib free base
|
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
|
HRP20220436T1
(hr)
|
2015-11-03 |
2022-05-27 |
Janssen Biotech, Inc. |
Protutijela koja se specifično vežu na pd-1 i njihove uporabe
|
|
JP7066613B2
(ja)
|
2015-11-12 |
2022-05-13 |
シージェン インコーポレイテッド |
グリカン相互作用化合物および使用方法
|
|
CN106749259B
(zh)
*
|
2015-11-19 |
2019-02-01 |
华东师范大学 |
一种环戊基嘧啶并吡咯类化合物的合成方法
|
|
CN106831780A
(zh)
*
|
2015-12-03 |
2017-06-13 |
南开大学 |
具有cdk4/6和hdac抑制活性的新型杂环衍生物
|
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
CN105541863B
(zh)
*
|
2016-02-16 |
2017-09-05 |
安纳康科学股份有限公司 |
噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
|
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
CN108884101B
(zh)
*
|
2016-03-25 |
2020-07-24 |
正大天晴药业集团股份有限公司 |
取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途
|
|
CN107266451B
(zh)
*
|
2016-04-07 |
2021-12-31 |
上海医药工业研究院 |
瑞布昔利布中间体的制备方法
|
|
WO2017185031A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
MX387648B
(es)
|
2016-05-07 |
2025-03-18 |
Fochon Pharmaceuticals Ltd |
Derivados de heteroarilo tieno[3,2-d]pirimidina-6-carboxamida de la fórmula (ii) que presentan actividad inhibitoria sobre cinasa cdk4/6.
|
|
WO2017211245A1
(zh)
*
|
2016-06-06 |
2017-12-14 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的吡咯并嘧啶化合物及其应用
|
|
CN109311848B
(zh)
|
2016-06-07 |
2022-02-01 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
JP7106462B2
(ja)
|
2016-07-01 |
2022-07-26 |
ジー１ セラピューティクス， インコーポレイテッド |
Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
|
|
JP2019520379A
(ja)
*
|
2016-07-01 |
2019-07-18 |
ジー１ セラピューティクス， インコーポレイテッド |
ピリミジン系の抗増殖剤
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
AU2017315357B2
(en)
|
2016-08-23 |
2022-12-01 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of hepatocellular carcinoma
|
|
WO2018051280A1
(en)
*
|
2016-09-15 |
2018-03-22 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of ribociclib, its acid addition salts
|
|
KR102341660B1
(ko)
|
2016-09-19 |
2021-12-23 |
노파르티스 아게 |
Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
BR112019005526A2
(pt)
|
2016-10-20 |
2019-06-18 |
Pfizer |
agentes antiproliferativos para tratamento de pah
|
|
WO2018081211A1
(en)
*
|
2016-10-26 |
2018-05-03 |
Li George Y |
Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
|
|
US11865176B2
(en)
|
2016-11-08 |
2024-01-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2018094227A1
(en)
*
|
2016-11-17 |
2018-05-24 |
The University Of North Carolina At Chapel Hill |
Alkyl pyrrolopyrimidine analogs and methods of making and using same
|
|
CN109996800B
(zh)
|
2016-11-28 |
2021-11-19 |
帝人制药株式会社 |
吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体
|
|
SI3546458T1
(sl)
|
2016-11-28 |
2021-03-31 |
Teijin Pharma Limited |
Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka
|
|
CA3045465A1
(en)
|
2016-12-05 |
2018-06-14 |
G1 Therapeutics, Inc. |
Preservation of immune response during chemotherapy regimens
|
|
EA201991622A1
(ru)
|
2017-01-06 |
2020-01-23 |
Г1 Терапьютикс, Инк. |
Комплексная терапия для лечения рака
|
|
WO2018140730A1
(en)
|
2017-01-27 |
2018-08-02 |
Signalrx Pharmaceuticals, Inc. |
Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
|
|
US11395821B2
(en)
|
2017-01-30 |
2022-07-26 |
G1 Therapeutics, Inc. |
Treatment of EGFR-driven cancer with fewer side effects
|
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
IL269357B2
(en)
|
2017-03-16 |
2024-10-01 |
Eisai R&D Man Co Ltd |
A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer
|
|
SMT202400385T1
(it)
|
2017-03-23 |
2024-11-15 |
Jacobio Pharmaceuticals Co Ltd |
Nuovi derivati eterociclici utili come inibitori di shp2
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
ES2952265T3
(es)
|
2017-05-02 |
2023-10-30 |
Novartis Ag |
Terapia combinada que comprende un inhibidor de Raf y trametinib
|
|
CN106946880B
(zh)
*
|
2017-05-06 |
2019-04-26 |
南京焕然生物科技有限公司 |
一种制备瑞博西尼中间体的方法
|
|
CN107118215B
(zh)
*
|
2017-05-06 |
2019-04-05 |
上海耀大生物科技有限公司 |
一种治疗乳腺癌药物瑞博西尼中间体的制备方法
|
|
CN107267481A
(zh)
*
|
2017-05-09 |
2017-10-20 |
上海交通大学医学院附属新华医院 |
Cdk5抗原表位肽及其应用
|
|
CN108929324A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
新型1,1-环丙基二酰胺衍生物的制备与应用
|
|
CN108929312A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
|
|
TW201906818A
(zh)
*
|
2017-05-31 |
2019-02-16 |
美商５１１製藥公司 |
新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
|
|
WO2018218633A1
(en)
|
2017-06-02 |
2018-12-06 |
Beijing Percans Oncology Co. Ltd. |
Combination therapies for treating cancers
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN110913861B
(zh)
|
2017-06-29 |
2024-01-09 |
G1治疗公司 |
G1t38的形态学形式及其制造方法
|
|
WO2019026006A1
(en)
|
2017-08-03 |
2019-02-07 |
Novartis Ag |
THERAPEUTIC ASSOCIATION OF THIRD GENERATION EGFR TYROSINE KINASE INHIBITOR AND CYCLIN D KINASE INHIBITOR
|
|
CA3073936A1
(en)
|
2017-08-25 |
2019-02-28 |
Sicor - Societa Italiana Corticosteroidi S.R.L. |
Ribociclib salts and solid state forms thereof
|
|
CN119162314A
(zh)
|
2017-08-31 |
2024-12-20 |
诺华股份有限公司 |
选择针对癌症患者的治疗的方法
|
|
US11286259B2
(en)
|
2017-09-29 |
2022-03-29 |
Hangzhou Solipharma Co., Ltd. |
Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
|
|
US11440912B2
(en)
|
2017-10-27 |
2022-09-13 |
Fresenius Kabi Oncology Ltd |
Process for the preparation of ribociclib and its salts
|
|
US11179365B2
(en)
|
2017-11-16 |
2021-11-23 |
Novartis Ag |
Pharmaceutical combination comprising LSZ102 and ribociclib
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
JP7569688B2
(ja)
*
|
2017-12-22 |
2024-10-18 |
ハイバーセル，インコーポレイテッド |
ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
|
|
WO2019123364A1
(en)
|
2017-12-22 |
2019-06-27 |
Shilpa Medicare Limited |
Novel polymorphs of ribociclib mono succinate
|
|
WO2019133864A1
(en)
*
|
2017-12-29 |
2019-07-04 |
Accutar Biotechnology |
DUAL INHIBITORS OF PARP1 and CDK
|
|
CN107936029B
(zh)
*
|
2018-01-08 |
2020-06-30 |
南京奇可药业有限公司 |
一种合成瑞博西尼的方法
|
|
PE20210121A1
(es)
|
2018-01-08 |
2021-01-19 |
G1 Therapeutics Inc |
Regimenes de dosificacion superior de g1t38
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
TW201940166A
(zh)
*
|
2018-01-29 |
2019-10-16 |
美商貝達醫藥公司 |
作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
|
|
CA3089592A1
(en)
|
2018-02-15 |
2019-08-22 |
Nuvation Bio Inc. |
Heterocyclic compounds as kinase inhibitors
|
|
WO2019167068A1
(en)
|
2018-03-01 |
2019-09-06 |
Cipla Limited |
Novel polymorphs of ribociclib succinate
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
CA3043066A1
(en)
|
2018-05-14 |
2019-11-14 |
Apotex Inc. |
Processes for the preparation of ribociclib and intermediates thereof
|
|
WO2019222521A1
(en)
*
|
2018-05-16 |
2019-11-21 |
G1 Therapeutics, Inc. |
Cdk inhibitors for the treatment of neoplastic disorders
|
|
CN108558745A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种帕博西林中间体的合成方法
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
SG11202012071TA
(en)
|
2018-06-05 |
2021-01-28 |
Crinetics Pharmaceuticals Inc |
Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
AU2019310595B2
(en)
|
2018-07-27 |
2022-11-24 |
1200 Pharma Llc |
CDK inhibitors and uses thereof
|
|
AU2019321289B2
(en)
|
2018-08-13 |
2025-01-23 |
Beijing Percans Oncology Co. Ltd. |
Biomarkers for cancer therapy
|
|
CN120817904A
(zh)
|
2018-08-24 |
2025-10-21 |
法码科思莫斯有限公司 |
1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
|
|
WO2020052627A1
(zh)
*
|
2018-09-13 |
2020-03-19 |
正大天晴药业集团股份有限公司 |
取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途
|
|
US20210393623A1
(en)
|
2018-09-26 |
2021-12-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
|
|
WO2020084389A1
(en)
|
2018-10-23 |
2020-04-30 |
Lupin Limited |
Ribociclib intermediate and process for preparation thereof
|
|
CA3117556A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CN109400612A
(zh)
*
|
2018-12-24 |
2019-03-01 |
重庆三圣实业股份有限公司 |
一种瑞博西尼的制备方法及其产品和用途
|
|
WO2020140054A1
(en)
|
2018-12-28 |
2020-07-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
US20220056037A1
(en)
*
|
2018-12-28 |
2022-02-24 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
CN113316471A
(zh)
|
2019-01-23 |
2021-08-27 |
诺华股份有限公司 |
7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7H-吡咯并[2,3-d]嘧啶-6-羧酸二甲基酰胺的琥珀酸盐的新的结晶形式
|
|
CN113382731A
(zh)
|
2019-02-12 |
2021-09-10 |
诺华股份有限公司 |
包含tno155和瑞博西尼的药物组合
|
|
CN113329792B
(zh)
|
2019-02-15 |
2024-06-28 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
CN114364675A
(zh)
|
2019-05-05 |
2022-04-15 |
上海齐鲁锐格医药研发有限公司 |
Cdk抑制剂
|
|
WO2020225827A1
(en)
|
2019-05-08 |
2020-11-12 |
Mylan Laboratories Limited |
Novel polymorphs of ribociclib succinate
|
|
EP3969449B1
(en)
|
2019-05-13 |
2025-02-12 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
CN114728076A
(zh)
|
2019-05-20 |
2022-07-08 |
诺华股份有限公司 |
Mcl-1抑制剂抗体-药物缀合物及使用方法
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
CN114008039B
(zh)
*
|
2019-06-04 |
2024-01-16 |
斯泰普制药股份公司 |
作为人ctps1抑制剂用于治疗增殖性疾病的化合物
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
IL290789B2
(en)
|
2019-08-26 |
2025-09-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
WO2021038590A1
(en)
|
2019-08-30 |
2021-03-04 |
Mylan Laboratories Limited |
Novel polymorph of ribociclib succinate
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
EP4054583A4
(en)
*
|
2019-11-07 |
2023-10-25 |
Crinetics Pharmaceuticals, Inc. |
MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES
|
|
BR112022011758A2
(pt)
*
|
2019-12-16 |
2022-08-30 |
Lunella Biotech Inc |
Terapêutica de câncer inibidor de cdk4/6 seletivo
|
|
KR20220113986A
(ko)
|
2019-12-16 |
2022-08-17 |
루넬라 바이오테크 인코포레이티드 |
선택적 cdk 4/6 억제제 암 치료제
|
|
AU2020406350A1
(en)
|
2019-12-20 |
2022-08-11 |
Novartis Ag |
Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
EP4603142A3
(en)
|
2019-12-23 |
2025-08-27 |
Crinetics Pharmaceuticals, Inc. |
Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
WO2021133886A1
(en)
|
2019-12-23 |
2021-07-01 |
Accutar Biotechnology |
Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
|
|
US20230118053A1
(en)
*
|
2020-03-27 |
2023-04-20 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
|
|
US20240000789A1
(en)
|
2020-05-12 |
2024-01-04 |
Novartis Ag |
Therapeutic combinations comprising a craf inhibitor
|
|
WO2021227906A1
(zh)
*
|
2020-05-12 |
2021-11-18 |
苏州阿尔脉生物科技有限公司 |
一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
|
|
CN113149996B
(zh)
*
|
2020-05-12 |
2022-12-20 |
苏州阿尔脉生物科技有限公司 |
一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
|
|
EP4652997A2
(en)
|
2020-05-19 |
2025-11-26 |
Pharmacosmos Holding A/s |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
EP4165046B1
(en)
*
|
2020-06-11 |
2025-09-17 |
Lunella Biotech, Inc. |
Selective cdk4/6 inhibitor cancer therapeutics
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
CN112375081B
(zh)
*
|
2020-11-23 |
2022-04-12 |
中国医学科学院医药生物技术研究所 |
具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
|
|
MX2023006010A
(es)
|
2020-11-24 |
2023-06-08 |
Novartis Ag |
Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos.
|
|
KR20230138444A
(ko)
|
2020-11-24 |
2023-10-05 |
노파르티스 아게 |
Mcl-1 억제제 항체-약물 접합체 및 사용 방법
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
IL304891A
(en)
|
2021-02-02 |
2023-10-01 |
Servier Lab |
Selective Protech BCL-XL compounds and methods of use
|
|
JP2024510260A
(ja)
|
2021-03-19 |
2024-03-06 |
クリネティックス ファーマシューティカルズ，インク． |
疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト
|
|
EP4313987A2
(en)
|
2021-04-01 |
2024-02-07 |
KRKA, d.d., Novo mesto |
Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN117177752A
(zh)
|
2021-05-05 |
2023-12-05 |
诺华股份有限公司 |
用于治疗mpnst的化合物和组合物
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
AU2022320615B2
(en)
|
2021-07-26 |
2025-08-21 |
Celcuity Inc. |
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
|
|
KR20240041340A
(ko)
*
|
2021-07-27 |
2024-03-29 |
보로노이 주식회사 |
피롤로피리미딘 유도체 화합물 및 이의 용도
|
|
TWI848533B
(zh)
|
2022-01-25 |
2024-07-11 |
瑞士商諾華公司 |
瑞博西尼藥物組成物
|
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
|
AU2023248394A1
(en)
*
|
2022-04-08 |
2024-10-31 |
Baerenkraft Therapeutics, Llc |
Cdk9 inhibitors
|
|
AU2023250538A1
(en)
*
|
2022-04-08 |
2024-10-31 |
Baerenkraft Therapeutics, Llc |
Cdk9 inhibitors
|
|
IL317103A
(en)
|
2022-05-20 |
2025-01-01 |
Novartis Ag |
Antibody-drug conjugates of MET inhibitor BCL-XL and methods of using them
|
|
EP4525925A1
(en)
|
2022-05-20 |
2025-03-26 |
Novartis AG |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
IL319242A
(en)
|
2022-08-31 |
2025-04-01 |
Arvinas Operations Inc |
Estrogen Receptor Blocker Dosage Regimen
|
|
EP4605088A1
(en)
*
|
2022-10-21 |
2025-08-27 |
Novartis AG |
Molecular glue degrader compounds and uses thereof
|
|
EP4615431A1
(en)
|
2022-11-11 |
2025-09-17 |
Astrazeneca AB |
Combination therapies for the treatment of cancer
|
|
EP4626890A1
(en)
|
2022-12-01 |
2025-10-08 |
KRKA, d.d., Novo mesto |
Ribociclib salts and formulations thereof
|
|
AU2024234194A1
(en)
|
2023-03-10 |
2025-08-07 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
TW202508598A
(zh)
|
2023-05-05 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
癌症療法
|
|
WO2024235844A1
(en)
|
2023-05-12 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods of preventing on-target genotoxicity induced by nucleases
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
CN117069663B
(zh)
*
|
2023-08-31 |
2023-12-26 |
四川维亚本苑生物科技有限公司 |
一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
|
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
|
WO2025080628A1
(en)
*
|
2023-10-10 |
2025-04-17 |
Biolexis Therapeutics, Inc. |
Bifunctional protac and molecular glue compounds and methods of use thereof
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025111450A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd74 antibody-drug conjugates and methods of use thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025217307A1
(en)
|
2024-04-09 |
2025-10-16 |
Revolution Medicines, Inc. |
Methods for predicting response to a ras(on) inhibitor and combination therapies
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
US20250319032A1
(en)
|
2024-04-15 |
2025-10-16 |
Novartis Ag |
Pharmaceutical compositions of ribociclib
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN120441576B
(zh)
*
|
2025-07-08 |
2025-09-26 |
山东大学 |
一种靶向cdk4/6的化合物及其衍生的放射性示踪剂
|
|
CN120483984B
(zh)
*
|
2025-07-09 |
2025-10-10 |
山东大学 |
一种靶向cdk4/6的分子影像探针标记前体、探针及其制备方法与应用
|